
SYRS
Healthcare · Biotechnology · $2,683 market cap
$0.00010.00 (0.0%)Nov 13, 9:30 AM EST
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2024
EPS trend, 90 days to now · +6.1% over 90 days · 30-day revisions 3 up, 2 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| May 12, 2026 | Time not confirmed | — | 0.00 | — |
| Mar 25, 2026 | Time not confirmed | -0.16 | 0.00 | +100.0% |
| Nov 28, 2025 | Time not confirmed | -0.20 | 0.00 | +100.0% |
| Aug 29, 2025 | Time not confirmed | -0.24 | 0.00 | +100.0% |
| May 30, 2025 | Time not confirmed | -0.54 | 0.00 | +100.0% |
| Mar 6, 2025 | Time not confirmed | -0.73 | -0.65 | +11.0% |
| Oct 31, 2024 | Before the open | -0.67 | -0.16 | +76.1% |
| Jul 31, 2024 | Before the open | -0.76 | -0.59 | +22.4% |
| May 14, 2024 | Before the open | -0.87 | -0.10 | +88.5% |
| Mar 27, 2024 | Before the open | -1.11 | -2.22 | -100.0% |
| Nov 14, 2023 | Before the open | -1.14 | -1.35 | -18.4% |
| Aug 8, 2023 | Before the open | -1.13 | -1.30 | -15.0% |
| May 10, 2023 | Before the open | -1.04 |
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia;…
| -0.85 |
| +18.3% |
| Mar 2, 2023 | Before the open | -1.35 | -0.17 | +87.4% |
| Nov 14, 2022 | Before the open | -4.40 | -3.21 | +27.0% |
| Aug 9, 2022 | Before the open | -4.15 | -5.40 | -30.1% |
| May 16, 2022 | Before the open | -4.72 | -4.00 | +15.3% |
| Mar 15, 2022 | Before the open | -4.66 | -3.80 | +18.5% |
| Nov 5, 2021 | Before the open | -4.36 | -4.10 | +6.0% |
| Aug 5, 2021 | Before the open | -3.74 | -3.60 | +3.7% |
| May 6, 2021 | Before the open | -4.90 | -2.30 | +53.1% |
| Mar 4, 2021 | Before the open | -4.99 | -6.20 | -24.2% |
| Nov 5, 2020 | After the close | -4.02 | -4.30 | -7.0% |
| Aug 6, 2020 | Before the open | -4.20 | -3.80 | +9.5% |
| May 7, 2020 | Before the open | -4.66 | -3.90 | +16.3% |
| Mar 5, 2020 | Before the open | -4.68 | -4.60 | +1.7% |
| Nov 12, 2019 | Before the open | -4.80 | -4.70 | +2.1% |
| Aug 1, 2019 | Before the open | -4.10 | -4.70 | -14.6% |
| May 1, 2019 | Before the open | -5.60 | -4.90 | +12.5% |
| Mar 7, 2019 | Before the open | -4.90 | -5.40 | -10.2% |
| Nov 1, 2018 | Before the open | -4.54 | -4.70 | -3.5% |
| Aug 7, 2018 | Before the open | -4.97 | -4.30 | +13.5% |
| May 10, 2018 | Before the open | -3.86 | -4.80 | -24.4% |
| Mar 12, 2018 | Before the open | -5.72 | -5.80 | -1.4% |